Abbott gains US FDA approval and CE mark for UltiSynq defibrillation lead
Article excerpt
Highlighted: the sentence this signal was extracted from
Abbott has announced that it has received US Food and Drug Administration (FDA) approval and a CE mark for the UltiSynq defibrillation lead, which is designed for implantation in the left bundle branch area (LBBA) of the heart to deliver both conduction system pacing (CSP) and defibrillation therapy. These approvals covering the USA and EU provide an additional lead option for patients who are candidates for both CSP and defibrillation protection, as noted in an Abbott press release. The release also states that the UltiSynq defibrillation lead is designed for long-term attachment to compatible implantable cardioverter-defibrillator (ICD) or cardiac resynchronisation therapy defibrillator (CRT-D) systems in patients who are at risk of sudden cardiac death due to life-threatening tachyarrhythmias. The US FDA and CE-mark approvals of the UltiSynq defibrillation lead were supported by results from the ASCEND CSP investigational device exemption (IDE) trial - a prospective, multicentre, global study evaluating the safety and effectiveness of UltiSynq in patients indicated for therapy involving an ICD or CRT-D device. Presented as late-breaking data at the 2026 Heart Rhythm Society (HRS) annual meeting (23–26 April, Chicago, USA), three-month results from the study demonstrated that the UltiSynq defibrillation lead exceeded all prespecified primary safety and effectiveness...
Keep reading with a free account
The rest of this article, and every signal for Abbott, is in your free account.
